HeartWare International, Inc. (HTWR)

[aproimos]

HeartWare overweight rating reissued by JPMorgan Chase.

HeartWare had its overweight rating reissued by analysts at JPMorgan Chase. The analysts wrote, “We view Heartware as one of the most compelling growth stories in small-cap MedTech. With its unique pump design, Heartware is poised to be the first real challenger to Thoratec’s near-monopoly position in the VAD market, which we view as one of the more promising growth segments in the cardiovascular universe over the next decade. The HVAD’s small size means the pump can be implanted directly within the pericardial space, allowing for less invasive implant techniques and potentially reducing complications. Heartware also expects first-in-man implants using its miniaturized next-generation pump, the MVAD, by mid-2013.”